'Perfect time': SIGA's CEO on retirement; Juvenescence woos GSK vet to lead anti-aging play
In the 1990s, Phil Gomez recalls the UK government launching what would be akin to a quasi-Operation Warp Speed in today’s parlance, as the region was facing high cases of meningitis C in children under the age of 5.
The chemical engineer by training was working at North American Vaccine and helped the company launch a jab to help curtail the toll in the UK. He grew an appreciation for public-private partnerships, especially when national governments and the biopharma and vaccine manufacturing industries align.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.